喜訊!佰鴻干細胞獲國檢認證通過,戰疫情再添利器
瀏覽次數: 0
佰鴻再生自主研(yan)發的無血清培養(yang)體系制備的人臍帶(dai)間(jian)充質干細胞(bao)制劑,日前已(yi)成功(gong)通過中(zhong)國(guo)食品藥品檢(jian)定(ding)研(yan)究院(yuan)的權威檢(jian)定(ding)認證——生物學安全性(xing)和有效性(xing)均已(yi)達到目前我(wo)國(guo)在(zai)臨床應用安全的國(guo)家標準(zhun)。
佰鴻(hong)再生現已建立(li)了GMP標準的(de)細胞(bao)(bao)制(zhi)備中心,擁有規范的(de)臨床級(ji)細胞(bao)(bao)制(zhi)劑生產(chan)體(ti)系(xi)(xi)和完善的(de)質量管理體(ti)系(xi)(xi)。此(ci)次檢定認證,將進一步促進再生干(gan)細胞(bao)(bao)技術與產(chan)品(pin)的(de)臨床轉(zhuan)化應用,有望在這次抗(kang)新(xin)冠病毒戰役(yi)中發揮(hui)重要作用。
佰(bai)(bai)鴻再(zai)(zai)生(sheng)旗下(xia)擁有(you)廣東芙金干細(xi)胞(bao)再(zai)(zai)生(sheng)醫學(xue)有(you)限(xian)公司(si)(si)(si)和陜西佰(bai)(bai)傲干細(xi)胞(bao)再(zai)(zai)生(sheng)醫學(xue)有(you)限(xian)公司(si)(si)(si)(為(wei)廣東芙金干細(xi)胞(bao)再(zai)(zai)生(sheng)有(you)限(xian)公司(si)(si)(si)全資子(zi)公司(si)(si)(si))兩地干細(xi)胞(bao)轉化研究中(zhong)心。佰(bai)(bai)鴻再(zai)(zai)生(sheng)在廣東和陜西擁有(you)一體雙中(zhong)心干細(xi)胞(bao)制(zhi)劑(ji)(ji)生(sheng)產的(de)(de)(de)強大(da)能力(li)。陜西佰(bai)(bai)傲干細(xi)胞(bao)公司(si)(si)(si)利用廣東芙金干細(xi)胞(bao)公司(si)(si)(si)自主研發(fa)的(de)(de)(de)無血(xue)清(qing)培養(yang)體系,通過細(xi)胞(bao)工廠規(gui)模化培養(yang)制(zhi)備的(de)(de)(de)人臍帶間充質干細(xi)胞(bao)制(zhi)劑(ji)(ji)。日前,已(yi)成功通過中(zhong)國食(shi)品(pin)藥(yao)品(pin)檢定(ding)研究院(yuan)(以下(xia)簡稱中(zhong)檢院(yuan))的(de)(de)(de)權威檢定(ding)認證——干細(xi)胞(bao)制(zhi)劑(ji)(ji)的(de)(de)(de)生(sheng)物學(xue)安全性(xing)和有(you)效性(xing)均(jun)已(yi)達到目前我國在臨床應用安全的(de)(de)(de)國家標準。
中(zhong)檢(jian)(jian)院是國家檢(jian)(jian)驗(yan)(yan)(yan)藥品生(sheng)物制(zhi)(zhi)(zhi)品質(zhi)(zhi)(zhi)量的(de)(de)法定(ding)(ding)機構和(he)(he)(he)最高技術仲裁機構,具(ju)(ju)有(you)(you)(you)(you)實(shi)驗(yan)(yan)(yan)室(shi)認(ren)可(CNAS)和(he)(he)(he)資質(zhi)(zhi)(zhi)認(ren)定(ding)(ding)(CMA)資格的(de)(de)國家級檢(jian)(jian)定(ding)(ding)實(shi)驗(yan)(yan)(yan)室(shi)。中(zhong)檢(jian)(jian)院檢(jian)(jian)驗(yan)(yan)(yan)報告是和(he)(he)(he)三(san)甲醫院開展間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)臨(lin)(lin)(lin)床(chuang)研究的(de)(de)必備(bei)條(tiao)件之一(yi)。 佰(bai)(bai)鴻實(shi)力(li),彰顯王牌品質(zhi)(zhi)(zhi)佰(bai)(bai)鴻再生(sheng)現(xian)已建立(li)了GMP標準的(de)(de)間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)制(zhi)(zhi)(zhi)備(bei)中(zhong)心,擁有(you)(you)(you)(you)規范的(de)(de)臨(lin)(lin)(lin)床(chuang)級細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)制(zhi)(zhi)(zhi)劑生(sheng)產體(ti)系(xi)和(he)(he)(he)完(wan)善(shan)的(de)(de)質(zhi)(zhi)(zhi)量管理體(ti)系(xi)。旗下(xia)公(gong)司(si)已承擔多(duo)(duo)項干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)相關國家重點(dian)研發(fa)計劃(hua),特(te)別(bie)是以芙(fu)金干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)公(gong)司(si)為代表(biao)承擔的(de)(de)間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)規模(mo)(mo)化(hua)培(pei)養擴(kuo)增課題,已實(shi)現(xian)了基于細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)工廠(chang)的(de)(de)無(wu)血(xue)清規模(mo)(mo)化(hua)培(pei)養制(zhi)(zhi)(zhi)備(bei)。本次檢(jian)(jian)測(ce)報告顯示(shi),佰(bai)(bai)鴻再生(sheng)的(de)(de)人(ren)(ren)臍(qi)帶(dai)(dai)(dai)間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)制(zhi)(zhi)(zhi)劑,總計完(wan)成(cheng)(cheng)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)鑒別(bie)、無(wu)菌檢(jian)(jian)測(ce)、支原體(ti)檢(jian)(jian)測(ce)、外源(yuan)(yuan)病(bing)(bing)毒檢(jian)(jian)測(ce)(體(ti)外法)、外源(yuan)(yuan)病(bing)(bing)毒檢(jian)(jian)測(ce)(體(ti)內(nei)法)、特(te)殊人(ren)(ren)源(yuan)(yuan)病(bing)(bing)毒檢(jian)(jian)測(ce)、免(mian)疫(yi)(yi)學反應(ying)(ying)檢(jian)(jian)測(ce)、誘導(dao)(dao)分(fen)化(hua)能(neng)力(li)檢(jian)(jian)測(ce)、成(cheng)(cheng)瘤性(xing)檢(jian)(jian)測(ce)、細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)活性(xing)檢(jian)(jian)測(ce)等10個(ge)大(da)項(39個(ge)小(xiao)項)的(de)(de)測(ce)試(shi)(shi),其(qi)所(suo)有(you)(you)(you)(you)項目(mu)均符合(he)或優于檢(jian)(jian)驗(yan)(yan)(yan)標準,具(ju)(ju)有(you)(you)(you)(you)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)純度高,免(mian)疫(yi)(yi)調(diao)節能(neng)力(li)好,誘導(dao)(dao)分(fen)化(hua)能(neng)力(li)強等諸多(duo)(duo)優勢。更重要的(de)(de)是,由佰(bai)(bai)鴻再生(sheng)自主研發(fa)的(de)(de)無(wu)血(xue)清培(pei)養液、細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)工廠(chang)規模(mo)(mo)化(hua)培(pei)養工藝等構成(cheng)(cheng)的(de)(de)培(pei)養體(ti)系(xi)可以維持間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)狀態良好,所(suo)有(you)(you)(you)(you)檢(jian)(jian)測(ce)項目(mu)在(zai)P10代依然合(he)格。這表(biao)明(ming),佰(bai)(bai)鴻再生(sheng)已建立(li)了一(yi)套完(wan)整的(de)(de)人(ren)(ren)臍(qi)帶(dai)(dai)(dai)間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)培(pei)養體(ti)系(xi)和(he)(he)(he)制(zhi)(zhi)(zhi)備(bei)工藝,能(neng)為臨(lin)(lin)(lin)床(chuang)應(ying)(ying)用(yong)提供質(zhi)(zhi)(zhi)量合(he)格的(de)(de)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)。神奇(qi)的(de)(de)間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)!間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)是一(yi)類來(lai)源(yuan)(yuan)于發(fa)育(yu)早期(qi)中(zhong)胚層的(de)(de)多(duo)(duo)能(neng)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao),是目(mu)前研究最多(duo)(duo)、最重要的(de)(de)成(cheng)(cheng)體(ti)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)之一(yi)。與其(qi)他來(lai)源(yuan)(yuan)相比,來(lai)源(yuan)(yuan)于人(ren)(ren)臍(qi)帶(dai)(dai)(dai)的(de)(de)間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)具(ju)(ju)有(you)(you)(you)(you)采集方(fang)便、無(wu)倫理爭議、免(mian)疫(yi)(yi)原性(xing)低、自我更新快、倍增速度穩定(ding)(ding)和(he)(he)(he)增殖能(neng)力(li)強等特(te)點(dian)。因(yin)此,人(ren)(ren)臍(qi)帶(dai)(dai)(dai)間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)適合(he)用(yong)于臨(lin)(lin)(lin)床(chuang)研究和(he)(he)(he)應(ying)(ying)用(yong),是細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)治療和(he)(he)(he)再生(sheng)醫學的(de)(de)首選。間(jian)充(chong)(chong)質(zhi)(zhi)(zhi)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)在(zai)疾(ji)病(bing)(bing)治療方(fang)面被(bei)寄予(yu)厚望。目(mu)前已被(bei)廣泛(fan)應(ying)(ying)用(yong)到(dao)多(duo)(duo)種(zhong)疾(ji)病(bing)(bing)的(de)(de)治療研究中(zhong),我們國家有(you)(you)(you)(you)近70個(ge)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)臨(lin)(lin)(lin)床(chuang)研究項目(mu)通過備(bei)案,10余(yu)款干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)新藥臨(lin)(lin)(lin)床(chuang)試(shi)(shi)驗(yan)(yan)(yan)申請獲得受(shou)理,5款干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)新藥臨(lin)(lin)(lin)床(chuang)試(shi)(shi)驗(yan)(yan)(yan)申請獲得了默示(shi)許可。戰疫(yi)(yi)情,佰(bai)(bai)鴻再添利器。
佰鴻再生目(mu)前已在(zai)肝(gan)硬化(hua)(hua)、糖尿病(bing)和關節炎(yan)等適應(ying)癥中(zhong)(zhong)完成了臨(lin)床(chuang)前研究(jiu),現已與多家(jia)三甲醫院建立密切的(de)(de)合作關系,此次干細胞制劑產品成功通過中(zhong)(zhong)檢院檢定檢測(ce),將進(jin)一步(bu)加強公司干細胞技術與產品的(de)(de)臨(lin)床(chuang)轉(zhuan)化(hua)(hua)應(ying)用(yong)(yong)。當前,間充質干細胞憑借著巨(ju)大的(de)(de)疾病(bing)治(zhi)(zhi)療(liao)前景,被應(ying)用(yong)(yong)到(dao)多個新(xin)型冠狀病(bing)毒肺(fei)(fei)炎(yan)重(zhong)(zhong)癥患(huan)者治(zhi)(zhi)療(liao)的(de)(de)臨(lin)床(chuang)研究(jiu)項目(mu)中(zhong)(zhong)。如今,在(zai)面對新(xin)型冠狀病(bing)毒感(gan)染的(de)(de)肺(fei)(fei)炎(yan)患(huan)者,干細胞的(de)(de)治(zhi)(zhi)療(liao)探索陸(lu)續獲(huo)批(pi)立項。隨著研究(jiu)的(de)(de)廣泛開展,間充質干細胞的(de)(de)免(mian)疫調節特性(xing)、抗炎(yan)特性(xing)以及(ji)修復受損組織的(de)(de)特性(xing)有望在(zai)這次抗病(bing)毒戰(zhan)役中(zhong)(zhong)發揮重(zhong)(zhong)要(yao)作用(yong)(yong)。